Enanta Pharmaceuticals to Present at the 2013 Credit Suisse Healthcare Conference
November 06 2013 - 4:30PM
Business Wire
Enanta Pharmaceuticals, Inc., (NASDAQ:ENTA) a
research and development-focused biotechnology company dedicated to
creating small molecule drugs in the infectious disease field,
today announced that Jay R. Luly, Ph.D., President and Chief
Executive Officer, will present a corporate overview on November 13
at 3:30 p.m. MST, during the 2013 Credit Suisse Healthcare
Conference in Scottsdale, Arizona.
The presentation session will be webcast live
and a replay can be accessed by visiting the Investor homepage
section of Enanta’s website at www.enanta.com. A replay of the
webcast will be available following the presentation and will be
archived for approximately 30 days.
About Enanta
Enanta Pharmaceuticals is a research and
development-focused biotechnology company that uses its robust
chemistry-driven approach and drug discovery capabilities to create
small molecule drugs in the infectious disease field. Enanta is
discovering and developing novel inhibitors designed for use
against the hepatitis C virus (HCV). These inhibitors include
members of the direct acting antiviral (DAA) inhibitor classes –
protease (partnered with AbbVie), NS5A (partnered with Novartis)
and nucleotide polymerase – as well as a host-targeted antiviral
(HTA) inhibitor class targeted against cyclophilin. Additionally,
Enanta has created a new class of antibiotics, called Bicyclolides,
for the treatment of multi-drug resistant bacteria, with a focus on
developing an intravenous and oral treatment for hospital and
community MRSA (methicillin-resistant Staphylococcus aureus)
infections.
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024